Bicyclic pyrazolone compounds and methods of use
The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.
1. A compound having Formula (I):
or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein:
Q is H, OR a , NR a R b , —C(═O)NR a R b , —N(R c )C(═O)R d , —N(R c )C(═O)OR a or —N(R c )C(═O)NR a R b ;
U is CR 7 or N, provided that when U is N, the compound is not 2-oxo-1-phenyl-N-(5-((2-(pyrrolidine-1-carboxamido)pyridin-4-yl)oxy)pyridin-2-yl)-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide or 1-(buta-1,3-dien-2- yl)-2-oxo-N-(5-((2-(pyrrolidine-1-carboxamido) pyridin-4-yl)oxy)pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyrazine-3-carboxamide;
X is H, C 1 -C 6 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, C 3 -C 8 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 8 cycloalkyl), 3-8 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-8 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl or —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl), wherein each of the C 1 -C 6 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, C 3 -C 8 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 8 cycloalkyl), 3-8 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-8 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl and —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl) is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from F, Cl, Br, CN, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, OR a , NR a R b , —(C 1 -C 4 alkylene)-OR a and —(C 1 -C 4 alkylene)-NR a R b ;
each Y is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 8 cycloalkyl), 3-8 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-8 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl, —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl), OR a , NR a R b , —(C 1 -C 4 alkylene)-OR a or —(C 1 -C 4 alkylene)-NR a R b ;
m is 0, 1, 2, 3, 4;
W is —(CH 2 ) n —, —(CH 2 ) n O—, —(CH 2 ) n NH— or —(CH 2 ) n S—, wherein n is 0, 1, 2, 3 or 4;
each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is independently H, F, Cl, Br, CN, N 3 , OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;
each of R a , R b and R c is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-6 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl or —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl), or R a and R b taken together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclic ring, wherein each of the C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-6 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl, —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl) and 3-8 membered heterocyclic ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, CN, N 3 , OH, NH 2 , C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy and C 1 -C 6 alkylamino; and
R d is H, C 1 -C 6 alkyl, C 3 C 8 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 8 cycloalkyl), 3-8 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-8 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl or —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl), wherein each of the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, —(C 1 -C 4 alkylene)-(C 3 -C 8 cycloalkyl), 3-8 membered heterocyclyl, —(C 1 -C 4 alkylene)-(3-8 membered heterocyclyl), C 6 -C 10 aryl, —(C 1 -C 4 alkylene)-(C 6 -C 10 aryl), 5-10 membered heteroaryl and —(C 1 -C 4 alkylene)-(5-10 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, CN, OR a , NR a R b , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —(C 1 -C 4 alkylene)-OR a and —(C 1 -C 4 alkylene)-NR a R b .
2. The compound of claim 1 , wherein X is C 1 -C 4 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), phenyl or —(C 1 -C 2 alkylene)-phenyl, wherein each of the C 1 -C 4 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), phenyl and —(C 1 -C 2 alkylene)-phenyl is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from F, Cl, Br, CN, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, OR a , NR a R b , —(C 1 -C 2 alkylene)-OR a and —(C 1 -C 2 alkylene)-NR a R b .
3. The compound of claim 1 , wherein each Y is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl, —(C 1 -C 2 alkylene)-(3-6 membered heterocyclyl), phenyl, —(C 1 -C 2 alkylene)-phenyl, 5-6 membered heteroaryl, —(C 1 -C 2 alkylene)-(5-6 membered heteroaryl), OR a , NR a R b , —(C 1 -C 2 alkylene)-OR a or —(C 1 -C 2 alkylene)-NR a R b ; m is 0, 1 or 2.
4. The compound of claim 1 , wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is independently H, F, Cl, Me or OMe.
5. The compound of claim 1 , wherein each of R a , R b and R c is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl or —(C 1 -C 2 alkylene)-(3-6 membered heterocyclyl), or R a and R b taken together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclic ring, wherein each of the C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl, —(C 1 -C 2 alkylene)-(3-6 membered heterocyclyl) and 3-8 membered heterocyclic ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, CN, N 3 , OH, NH 2 , C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy and C 1 -C 3 alkylamino.
6. The compound of claim 1 , wherein R d is H, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl or —(C 1 -C 2 alkylene)-(3-6 membered heterocyclyl), wherein each of the C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 2 alkylene)-(C 3 -C 6 cycloalkyl), 3-6 membered heterocyclyl and —(C 1 -C 2 alkylene)-(3-6 membered heterocyclyl) is optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, CN, OR a , NR a R b , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, —(C 1 -C 2 alkylene)-OR a and —(C 1 -C 2 alkylene)-NR a R b .
7. The compound of claim 1 , wherein Q is:
8. The compound of claim 1 having one of the following structures:
9. A pharmaceutical composition comprising the compound according to claim 1 , and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or a combination thereof.
10. The pharmaceutical composition of claim 9 further comprising a therapeutic agent selected from the group consisting of chemotherapeutic agents, anti-proliferative agents, agents for treating atherosclerosis, agents for treating lung fibrosis and combinations thereof.
11. The pharmaceutical composition of claim 10 , wherein the therapeutic agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin, ixabepilone, tamoxifen, flutamide, gonadorelin analogues, megestrol, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon alfa, leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximabvedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, ramucirumab, rituximab, tositumomab, trastuzumab or a combination thereof.
12. A method of treating or lessening the severity of a proliferative disease in a patient by administering to the patient with a therapeutically effective amount of the compound according to claim 1 , wherein the proliferative disease is atherosclerosis, lung fibrosis, colon cancer, rectal cancer, gastric cancer, gastric adenocarcinoma, pancreatic cancer, bladder cancer, gallbladder cancer, breast cancer, kidney cancer, renal cell carcinoma, liver cancer, hepatocellular carcinoma, lung cancer, skin cancer, melanoma, thyroid cancer, osteosarcomas, soft tissue sarcoma, a cancer of the head and neck, a cancer of the central nervous system, glioma, glioblastomas, ovarian cancer, uterine cancer, endometrial carcinoma, prostate cancer, acute myeloid leukemia or acute lymphoblastic leukemia, or a metastasis thereof.
13. A method of inhibiting or modulating the activity of a protein kinase in a biological sample comprising contacting the biological sample with the compound according to claim 1 .
14. The method of claim 13 , wherein the protein kinase is a receptor tyrosine kinase.
15. The method of claim 14 , wherein the receptor tyrosine kinase is Axl, Mer, c-Met, Ron or a combination thereof.
16. A method of treating or lessening the severity of a proliferative disease in a patient by administering to the patient with a therapeutically effective amount of the pharmaceutical composition according to claim 9 , wherein the proliferative disease is atherosclerosis, lung fibrosis, colon cancer, rectal cancer, gastric cancer, gastric adenocarcinoma, pancreatic cancer, bladder cancer, gallbladder cancer, breast cancer, kidney cancer, renal cell carcinoma, liver cancer, hepatocellular carcinoma, lung cancer, skin cancer, melanoma, thyroid cancer, osteosarcomas, soft tissue sarcoma, a cancer of the head and neck, a cancer of the central nervous system, glioma, glioblastomas, ovarian cancer, uterine cancer, endometrial carcinoma, prostate cancer, acute myeloid leukemia or acute lymphoblastic leukemia, or a metastasis thereof.
17. A method of inhibiting or modulating the activity of a protein kinase in a biological sample comprising contacting the biological sample with the pharmaceutical composition according to claim 9 .
18. The method of claim 17 , wherein the protein kinase is a receptor tyrosine kinase.
19. The method of claim 18 , wherein the receptor tyrosine kinase is Axl, Mer, c-Met, Ron or a combination thereof.